138 related articles for article (PubMed ID: 11407736)
1. Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy.
Hamada M; Shigematsu Y; Hara Y; Suzuki M; Ohtsuka T; Hiasa G; Ogimoto A; Saeki H; Suzuki J; Hiwada K
Jpn Circ J; 2001 Jun; 65(6):531-8. PubMed ID: 11407736
[TBL] [Abstract][Full Text] [Related]
2. Effect of cibenzoline, a class ia antiarrhythmic agent, on left ventricular diastolic function in hypertrophic cardiomyopathy.
Kondo I; Mizushige K; Nozaki S; Iwado Y; Masugata H; Kohno M; Matsuo H
Cardiovasc Drugs Ther; 2001 Sep; 15(5):459-65. PubMed ID: 11855665
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy: its relationship to transmitral Doppler flow profiles.
Hamada M; Aono J; Ikeda S; Watanabe K; Inaba S; Suzuki J; Ohtsuka T; Shigematsu Y
Circ J; 2007 Oct; 71(10):1540-4. PubMed ID: 17895548
[TBL] [Abstract][Full Text] [Related]
4. Impact of chronic use of cibenzoline on left ventricular pressure gradient and left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy.
Hamada M; Ikeda S; Ohshima K; Nakamura M; Kubota N; Ogimoto A; Shigematsu Y
J Cardiol; 2016 Mar; 67(3):279-86. PubMed ID: 26116980
[TBL] [Abstract][Full Text] [Related]
5. Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy.
Sekine T; Daimon M; Hasegawa R; Teramoto K; Kawata T; Tanaka N; Takei Y; Takazawa K; Yoshida K; Komuro I
Heart Vessels; 2006 Nov; 21(6):350-5. PubMed ID: 17143709
[TBL] [Abstract][Full Text] [Related]
6. Antiarrhythmic drug cibenzoline attenuates left ventricular pressure gradient and improves transmitral Doppler flow pattern in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction.
Hamada M; Shigematsu Y; Inaba S; Aono J; Ikeda S; Watanabe K; Ogimoto A; Ohtsuka T; Hara Y; Higaki J
Circ J; 2005 Aug; 69(8):940-5. PubMed ID: 16041163
[TBL] [Abstract][Full Text] [Related]
7. Effect of cibenzoline on regional left ventricular function in hypertrophic obstructive cardiomyopathy.
Kondo I; Mizushige K; Nozaki S; Hirao K; Iwado Y; Ohmori K; Matsuo H
Clin Cardiol; 2000 Sep; 23(9):689-96. PubMed ID: 11016020
[TBL] [Abstract][Full Text] [Related]
8. Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy.
Hamada M; Shigematsu Y; Ikeda S; Hara Y; Okayama H; Kodama K; Ochi T; Hiwada K
Circulation; 1997 Sep; 96(5):1520-4. PubMed ID: 9315541
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic interactions between Angiotensin-converting enzyme insertion/deletion polymorphism and response to cibenzoline in patients with hypertrophic obstructive cardiomyopathy.
Ogimoto A; Okayama H; Nagai T; Ohtsuka T; Suzuki J; Inoue K; Nishimura K; Saito M; Shigematsu Y; Hamada M; Miki T; Higaki J
J Cardiovasc Pharmacol; 2010 May; 55(5):506-10. PubMed ID: 20179607
[TBL] [Abstract][Full Text] [Related]
10. Myocardial fibrosis attenuates the effect of cibenzoline on left ventricular diastolic function in patients with hypertrophic cardiomyopathy.
Saito M; Okayama H; Yoshii T; Hiasa G; Sumimoto T; Inaba S; Nishimura K; Inoue K; Ogimoto A; Shigematsu Y; Funada J; Hamada M; Higaki J
J Cardiovasc Pharmacol; 2011 Feb; 57(2):207-12. PubMed ID: 21052009
[TBL] [Abstract][Full Text] [Related]
11. Effect of disopyramide on systolic and early diastolic time intervals in patients with hypertrophic cardiomyopathy.
Sumimoto T; Hamada M; Ohtani T; Shigematsu Y; Fujiwara Y; Sekiya M; Hiwada K
J Clin Pharmacol; 1991 May; 31(5):440-3. PubMed ID: 2050829
[TBL] [Abstract][Full Text] [Related]
12. Mitral regurgitation disappearance after cibenzoline treatment in a patient with hypertrophic obstructive cardiomyopathy.
Inada K; Komukai K; Mori C; Nagasawa H; Shibata T; Mochizuki S
Intern Med; 2004 Jan; 43(1):55-8. PubMed ID: 14964580
[TBL] [Abstract][Full Text] [Related]
13. [Left ventricular function at rest and during exercise and the effects of propranolol in patients with hypertrophic cardiomyopathy].
Amano K; Sakamoto T; Sugimoto T
J Cardiol Suppl; 1987; 16():35-51. PubMed ID: 3509682
[TBL] [Abstract][Full Text] [Related]
14. [Pulsed Doppler echocardiographic assessment of diastolic left ventricular hemodynamics in hypertrophic cardiomyopathy: relationship between the mode of left ventricular filling and the distribution of left ventricular hypertrophy].
Oki T; Asai M; Takemura H; Fukuda N; Sakai H; Tominaga T; Murao A; Ohshima C; Kusaka Y; Niki T
J Cardiogr; 1983 Sep; 13(3):523-35. PubMed ID: 6687193
[TBL] [Abstract][Full Text] [Related]
15. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.
Matsubara H; Nakatani S; Nagata S; Ishikura F; Katagiri Y; Ohe T; Miyatake K
J Am Coll Cardiol; 1995 Sep; 26(3):768-75. PubMed ID: 7642872
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of cibenzoline for chest oppression and ventricular arrhythmia during effort and alcohol consumption in a patient with hypertrophic obstructive cardiomyopathy: a case report].
Sasayama T; Horimoto M; Takeda T; Takenaka T; Inoue H; Igarashi K; Akino M; Kikuchi K
J Cardiol; 2000 Jun; 35(6):445-50. PubMed ID: 10884982
[TBL] [Abstract][Full Text] [Related]
17. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
Kajimoto K; Imai T; Minami Y; Kasanuki H
Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
[TBL] [Abstract][Full Text] [Related]
18. Cibenzoline attenuates coronary systolic reversal flow in a patient with hypertrophic obstructive cardiomyopathy: a case report.
Saihara K; Hamasaki S; Otsuji Y; Yoshitama T; Ishida S; Kataoka T; Okui H; Tei C
J Cardiol; 2006 Oct; 48(4):209-13. PubMed ID: 17066624
[TBL] [Abstract][Full Text] [Related]
19. An equation to predict the changes in peak left ventricular pressure in hypertrophic obstructive cardiomyopathy after treatment: application to the administration of disopyramide.
Niki K; Sugawara M; Tanino S; Iwade K; Hosoda S; Kasanuki H
Heart Vessels; 1999; 14(2):72-81. PubMed ID: 10651183
[TBL] [Abstract][Full Text] [Related]
20. Oral verapamil effects on global and regional left ventricular diastolic filling in hypertrophic cardiomyopathy.
Yamagishi T; Ozaki M; Kusukawa R
Jpn Circ J; 1990 Nov; 54(11):1365-73. PubMed ID: 2287041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
